Purchase this article with an account.
H. Fujishima, Y. Takano, D. Murat, M. Tanaka, N. Okada, A. Igarashi, K. Tsubota, K. Fukagawa; 0.1% Cyclosporine Eye Drops for Patients With Vernal Keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5845.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Cyclosporine, which has been implicated in immuno suppressive drugs, is known to effective for the treatment of allergic diseases. We have studied the efficacy of treatment for patients with vernal keratoconjunctivitis (VKC) of newly developed three times daily topical application of 0.1% cyclosporine.
We evaluated 30 patients with severe treat-resistant VKC with corneal complications for six month. Some of the patients suffer atopic dermatitis. 10 patients treated with 0.1% cyclosporine alone and other patients added 0.1% cyclosporine with anti-allergic eye drops and/or steroid, which had been used before starting 0.1% cyclosporine. Every month, the patients were evaluated for symptoms including itching, discharge, tearing, photophobia, foreign body sensation, pain. We observed signs such as conjunctival injection, edema, follicle, papilla formation, and corneal complications. Visual acuity and intraocular pressure were measured.
Symptoms were all improved by the end of 6 month period. Signs of edema, follicle, papilla and giant papilla formation, and corneal complications were improved from 1 month after treatment. Number of patients who used steroid was decreased. Visual acuity was improved and intraocular pressure was not increased. Side effects of one case of hordeolum and one case of herpes keratitis recurrence was observed. They were treated completely with adequate drugs.
0.1% Cyclosporine eye drops with or without conventional topical treatment was effective for patients with VKC. No other severe complications were observed.
This PDF is available to Subscribers Only